Innovations dans le traitement hormonal du cancer de la prostate localement avancé et/ou métastatique [Innovations in hormonal treatment for locally advanced and/or metastatic prostate cancer]

Audenet, F.;Rouprêt, M.;Tombal, Bertrand
(2011) Progrès en Urologie — Vol. 21, n° Suppl 3, p. S96-S101 (2011)

Files

Audenet-2011-Innovationsdansletraitement.pdf
  • Restricted Access
  • Adobe PDF
  • 293.01 KB
Request a copy

Details

Authors
Abstract
Discovered over 40 years ago, hormonal therapy remains the cornerstone therapy of advanced prostate cancer and continues to evolve. Suppression of serum testosterone remains the mainstay of systemic treatment of prostate cancer. Antagonists of LH-RH are now available and can prevent the castration delay of agonists. They seem to have a clinical benefit in terms of PSA control. During the phase of resistance to extracellular castration, the androgen receptor is the dominant element. Intracellular steroidogenesis can be blocked by Abiraterone. Amplification and mutation of the androgen receptor may be controlled by antiandrogens of second generation. Thus, these new molecules, already or soon available, will renew the strategy of prostate cancer treatment.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Audenet, F., Rouprêt, M., & Tombal, B. (2011). Innovations dans le traitement hormonal du cancer de la prostate localement avancé et/ou métastatique [Innovations in hormonal treatment for locally advanced and/or metastatic prostate cancer]. Progrès en Urologie, 21(Suppl 3), S96-S101. https://doi.org/10.1016/S1166-7087(11)70022-7 (Original work published 2011)